Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents

被引:15
作者
Dissoki, Samar [1 ]
Eshet, Renana [1 ]
Billauer, Hana [1 ]
Mishani, Eyal [1 ]
机构
[1] Hadassah Hebrew Univ Hosp, Dept Nucl Med, Cyclotron Radiochem Unit, IL-91120 Jerusalem, Israel
关键词
PET; EGFR; cancer; fluorine-18; imaging; GROWTH-FACTOR-RECEPTOR; IRREVERSIBLE INHIBITOR; ACQUIRED-RESISTANCE; GENE-MUTATIONS; IMAGING AGENT; LUNG-CANCER; TUMORS; GEFITINIB; CETUXIMAB; PANITUMUMAB;
D O I
10.1002/jlcr.1569
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of epidermal growth factor receptor tyrosine kinase (EGFR-TK) has emerged as a major approach for cancer-targeted therapy. Consequently, there has been a great interest in the use of labeled EGFR-TK inhibitors as positron emission tomography (PET) imaging agents. Currently, the developed agents did not yield adequate PET imaging of animal models probably due to poor solubility, rapid washout from blood, and low stability in vivo. In order to overcome these hurdles, new derivatives of previously reported inhibitors (ML04, 2) with decreased log P and increased solubility were designed and synthesized. These compounds (3-5) exhibited high autophosphorylation inhibitory potency with an IC50 of 5-35 nM, decreased log P's (3.1, 3.34, and 3.45, respectively), and significantly increased solubility (630, 300, and 120 mu g/mL, respectively) relative to the previously reported parent compound 2 (log P = 3.7, solubility = 3.5 mu g/mL). The labeling of compound 5 with [F-18] and compounds 3 and 4 with [C-11] and [I-124], respectively, involved a one-step radiosynthesis. Compounds 3-5 were obtained with a total decay-corrected radiochemical yields of 13, 31, and 5%, respectively, and were found to be stable in blood. The positive outcome achieved with compounds 3-5 merits further in vivo evaluation as PET bioprobes.
引用
收藏
页码:41 / 52
页数:12
相关论文
共 47 条
[1]   Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors [J].
Abourbeh, Galith ;
Dissoki, Samar ;
Jacobson, Orit ;
Litchi, Amir ;
Ben Daniel, Revital ;
Laki, Desirediu ;
Levitzki, Alexander ;
Mishani, Eyal .
NUCLEAR MEDICINE AND BIOLOGY, 2007, 34 (01) :55-70
[2]   Preclinical studies with erlotinib (Tarceva) [J].
Akita, RW ;
Sliwkowski, MX .
SEMINARS IN ONCOLOGY, 2003, 30 (03) :15-24
[3]   Targeting HERI/EGFR: A molecular approach to cancer therapy [J].
Arteaga, C .
SEMINARS IN ONCOLOGY, 2003, 30 (03) :3-14
[4]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[5]   Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer [J].
Berlin, Jordan ;
Posey, James ;
Tchekmedyian, Simon ;
Hu, Eddie ;
Chan, David ;
Malik, Imtiaz ;
Yang, Liqiang ;
Amado, Rafael G. ;
Hecht, J. Randolph .
CLINICAL COLORECTAL CANCER, 2007, 6 (06) :427-432
[6]   Cetuximab in the treatment of head and neck cancer [J].
Bernier, Jacques .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (11) :1539-1552
[7]   Monoclonal antibodies targeting the epidermal growth factor receptor [J].
Bianco, R ;
Daniele, G ;
Ciardiello, F ;
Tortora, G .
CURRENT DRUG TARGETS, 2005, 6 (03) :275-287
[8]   Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase [J].
Bonasera, TA ;
Ortu, G ;
Rozen, Y ;
Krais, R ;
Freedman, NMT ;
Chisin, R ;
Gazit, A ;
Levitzki, A ;
Mishani, E .
NUCLEAR MEDICINE AND BIOLOGY, 2001, 28 (04) :359-374
[9]   Adenosine kinase inhibitors.: 6.: Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds [J].
Bookser, BC ;
Ugarkar, BG ;
Matelich, MC ;
Lemus, RH ;
Allan, M ;
Tsuchiya, M ;
Nakane, M ;
Nagahisa, A ;
Wiesner, JB ;
Erion, MD .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) :7808-7820
[10]   Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4′-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for β-amyloid in Alzheimer's disease [J].
Cai, LS ;
Chin, FT ;
Pike, VW ;
Toyama, H ;
Liow, JS ;
Zoghbi, SS ;
Modell, K ;
Briard, E ;
Shetty, HU ;
Sinclair, K ;
Donohue, S ;
Tipre, D ;
Kung, MP ;
Dagostin, C ;
Widdowson, DA ;
Green, M ;
Gao, W ;
Herman, MM ;
Ichise, M ;
Innis, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (09) :2208-2218